KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) EBITDA (2017 - 2025)

Twist Bioscience (TWST) has disclosed EBITDA for 9 consecutive years, with -$30.5 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 4.0% to -$30.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$76.5 million through Dec 2025, up 61.25% year-over-year, with the annual reading at -$77.8 million for FY2025, 62.7% up from the prior year.
  • EBITDA for Q4 2025 was -$30.5 million at Twist Bioscience, down from -$26.9 million in the prior quarter.
  • The five-year high for EBITDA was $20.2 million in Q2 2025, with the low at -$85.6 million in Q2 2024.
  • Average EBITDA over 5 years is -$43.1 million, with a median of -$42.9 million recorded in 2022.
  • The sharpest move saw EBITDA tumbled 68.78% in 2021, then skyrocketed 123.57% in 2025.
  • Over 5 years, EBITDA stood at -$45.4 million in 2021, then increased by 5.12% to -$43.1 million in 2022, then rose by 0.56% to -$42.8 million in 2023, then rose by 25.91% to -$31.7 million in 2024, then rose by 4.0% to -$30.5 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$30.5 million, -$26.9 million, and $20.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.